Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)

This study has been completed.
Genzyme, a Sanofi Company
University of Cologne
Information provided by (Responsible Party):
German CLL Study Group Identifier:
First received: August 20, 2010
Last updated: September 23, 2016
Last verified: September 2016
Study hypothesis: Simultaneous FMC-Alemtuzumab administration followed by Alemtuzumab maintenance therapy in patients with T-PLL is feasible, safe and efficient.

Condition Intervention Phase
T-cell-prolymphocytic Leukemia
Drug: Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab
Drug: Alemtuzumab
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Combined Immunochemotherapy With Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients With Previously Treated or Untreated T-Prolymphocytic Leukemia

Resource links provided by NLM:

Further study details as provided by German CLL Study Group:

Primary Outcome Measures:
  • Remission Rate [ Time Frame: 2 years after trial started ]
    Efficacy of the FMC therapy and Alemtuzumab Percentage and 95%-confidence-interval of response rates (CR, CRi, nPR, PR, SD and PD) will be provided.

Secondary Outcome Measures:
  • Overall Survival Time [ Time Frame: 4 years after start of trial ]
    OS will be calculated from the patient´s time of recruitment to death from any cause.

Enrollment: 16
Study Start Date: June 2010
Study Completion Date: May 2014
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: FCM-A followed by A-maintenance
First treatment phase: Chemoimmunotherapy A-FMC maximum 4 cycles. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c.
Drug: Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab

I. First treatment phase: Chemoimmunotherapy A-FMC


Cycle 1+2:

10 mg s.c., days 1-3

Cycle 3+4:

CR: 10 mg s.c., days 1-3 PR/SD: 30 mg s.c., days 1-3 Fludarabine: 20 mg/m2 i.v., days 1-3 Mitoxantrone: 6 mg/m2 i.v., day 1 Cyclophosphamide: 200 mg/m2 i.v., days 1-3 Repeat day 29, maximum 4 cycles. II. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c. The maintenance therapy will start one month after the Final Staging and will be administered monthly during the first six months plus once in month 10 and 13.

Other Names:
  • Mabcampath
  • Fludarabine
  • Endoxan
  • Novantron
Drug: Alemtuzumab
maintenance with Alemtuzumab following a induction with combined immunochemotherapy consisting of Fludarabine, cyclophosphamide, mitoxantrone and alemtuzumab
Other Name: Mabcampath

Detailed Description:

As the median survival time of patients with T-PLL is less than 12 months, the treatment of T-PLL is a special challenge.

The overall response rates with conventional chemotherapy or Deoxycoformycin were low (about 30% and 40%), with the monoclonal antibody Alemtuzumab response rates of 50% to 70% were achieved, but the duration of the response was short.

In the previous trial (T PLL 1), the efficacy of the FMC regimen (FMC = Fludarabine, Mitoxantrone and Cyclophosphamide) was tested, a preliminary analysis of 16 patients revealed a response rate of more than 60% after FMC-polychemotherapy and 83% after the subsequent administration of Alemtuzumab.

The goal of the T-PLL2-protocol is to assess if the simultaneous administration of FMC-polychemotherapy and Alemtuzumab with a subsequent Alemtuzumab maintenance therapy is capable of improving the remission rate and the disease-free survival time in patients with T-PLL.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Untreated patients with T-prolymphocytic leukemia (T-PLL) according to WHO criteria or pretreated patients (max. one previous treatment) with T-PLL
  • Age ≥ 18 years
  • WHO performance status of 0-2
  • Life expectancy > 6 months
  • CIRS score >= 6
  • Left ventricular ejection fraction ≥50% confirmed by echo-cardiogram performed < 6 months before inclusion to the trial and after the end of a possible anthracycline containing pretreatment
  • Adequate liver function as indicated by a total bilirubin, AST and ALT >= 2 the institutional ULN value, unless directly attributable to the T-PLL
  • Creatinine clearance >= 70 ml/min calculated according to the formula of Cockcroft and Gault
  • Seronegativity for HIV, HBV or HCV confirmed by serological testing within 6 weeks prior to registration
  • Willingness of fertile male and female patients to use a highly effective contraceptive method with a Pearl-Index < 1 during and at least six months after the end of the study treatment (e.g. implants, injectables, oral contraceptives in combination with another contraceptive method, some IUDs, sexual abstinence or vasectomised partner)
  • Negative serum pregnancy test one week prior to treatment (required for female patients before and <2 years after onset of menopause)
  • Patient's written informed consent

Exclusion Criteria:

  • Clinically significant auto-immune cytopenia or clinically significant hemolytic anaemia with suspicion of immune origin, even if Coombs test is negative
  • Active secondary malignancy requiring treatment (except basal cell carcinoma or tumour curatively treated by surgery)
  • Medical condition requiring prolonged use of oral corticosteroids (> 1 month)
  • Cerebral dysfunction, legal incapacity
  • Any circumstance at the time of study entry that would preclude completion of the study and required follow-up
  • Active infection or severe infection (WHO 4th degree) within the last three months before inclusion to the study
  • Participation in any other clinical trial during this study
  • Known hypersensitivity to any of the study medications (Fludarabine, Cyclophosphamide, Mitoxantrone or Alemtuzumab)
  • Patients who have already received more than 60% of the recommended maximum cumulative dose of an anthracycline (Epirubicine, Adriamycine or Mitoxantrone).

This maximum cumulative dose is defined for the individual substances as follows:

  • Epirubicin 900 mg/m²
  • Daunorubicin 550 mg/m², (or 400 mg/m² if the patient received mediastinal irradiation)
  • Adriamycine (Doxorubicine) 550 mg/m²
  • Mitoxantrone 200 mg/m²

    • Patients who already received Fludarabine in combination with Cyclophosphamide or Mitoxantrone
    • Patients who received prior treatment with Alemtuzumab alone or in combination with a purine analogue and who did not achieve a PR that lasted at least 6 months
    • Patients who are employees of the Sponsor (University of Cologne) or the study sites.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01186640

University Hospital Cologne
Cologne, Germany, 50924
Sponsors and Collaborators
German CLL Study Group
Genzyme, a Sanofi Company
University of Cologne
Principal Investigator: Michael Hallek, Prof. MD German CLL Study Group
  More Information

Additional Information:
Responsible Party: German CLL Study Group Identifier: NCT01186640     History of Changes
Other Study ID Numbers: T-PLL2
2008-001421-34 ( EudraCT Number )
Study First Received: August 20, 2010
Last Updated: September 23, 2016
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by German CLL Study Group:

Additional relevant MeSH terms:
Leukemia, Prolymphocytic
Leukemia, Prolymphocytic, T-Cell
Neoplasms by Histologic Type
Leukemia, Lymphoid
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, T-Cell
Fludarabine phosphate
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites, Antineoplastic
Antiviral Agents
Anti-Infective Agents processed this record on April 24, 2017